Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NuCana plc - American Depositary Shares (NQ:NCNA)

1.010 UNCHANGED
Delayed Quote Updated: 1:52 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NuCana plc - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NUC-7738 is protected by over 85 issued patents worldwide 
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Appoints Ian Webster as Chief Financial Officer
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Appoints Theresa Bruce as Chief Operating Officer
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings 
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Compliant with All Nasdaq Continued Listing Criteria
Anticipated Cash Runway into 2029 
From NuCana plc
Via GlobeNewswire
News headline image
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces ADS Ratio Change
From NuCana plc
Via GlobeNewswire
News headline image
Element79 Gold Corp Shifts Focus to US Projects and Appoints New VP of Corporate Development – More Stocks Inside
Via AB Newswire
News headline image
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
From NuCana plc
Via GlobeNewswire
News headline image
Micro-Cap Surge: NCNA, HCTI, SPZI, PNPN.V in MedTech, AI, Healthcare, Energy, Metals, Minerals, Etc. – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
NuCana Announces Plan to Implement ADS Ratio Change
From NuCana plc
Via GlobeNewswire
News headline image
Clifton Mining (OTC: CFTN) Ramps Up Mining Operations – More Stocks Inside
Via AB Newswire
News headline image
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
Pennies on the Rise: HCTI, SWISF, ADHC, NCNA Gain Traction Amid LargeCap Uncertainty – More Stocks Inside
Via AB Newswire
News headline image
NuCana Prices $7 Million Registered Direct Offering
From NuCana plc
Via GlobeNewswire
News headline image
Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside…
Via AB Newswire
Topics Intellectual Property
News headline image
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile 
From NuCana plc
Via GlobeNewswire
News headline image
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
From NuCana plc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.